pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,391 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT782Endpoints585BioPharma Dive224onclive165BioSpace57Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • HHS advances plan to pay out Covid-19 vaccine injury claims
    A newly proposed HHS rule would establish a compensation mechanism for people who claim they were injured by Covid-19 vaccines, as a key panel that oversees broader vaccine injury payments remains…
    Endpoints · 17d ago↗ source
  • Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset
    After more than a decade of work and plenty of ups and downs, Roche has dropped its Huntington’s disease drug tominersen. The decision comes after tominersen did no better than placebo in a Phase…
    Endpoints · 17d ago↗ source
  • UK price watchdog recommends against Amgen's Lumakras in lung cancer
    The UK’s drug pricing watchdog said government reimbursement of Amgen’s lung cancer drug Lumakras should be cut off for new patients. In draft guidance released on Thursday, the National Institut…
← prev
page 13 of 56
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 17d ago↗ source
  • FDA criticizes Lundbeck for webpages on migraine treatment Vyepti
    The FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent…
    Endpoints · 17d ago↗ source
  • FDA quietly stops releasing CRLs
    The FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information. The pause follows a law firm in April
    Endpoints · 17d ago↗ source
  • Outbreak of diarrhea-causing parasite grows to more than 1,000 cases
    An outbreak of diarrhea-causing parasite has grown to more than 1,000 cases, making it one of the nation’s largest such outbreaks in years.
    STAT · 17d ago↗ source
  • STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
    An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will get sizable grants.
    STAT · 17d ago↗ source
  • The biggest health tech stories of 2026 — so far
    We’re more than halfway through 2026, and it’s been an eventful year. Here are the five biggest developments we noticed in the first six months. Major AI companies are coming for healthcare.
    Endpoints · 17d ago↗ source
  • STAT+: FDA finalists under review
    Three top contenders to run the FDA are under review by the White House
    STAT · 17d ago↗ source
  • Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
    Plus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...
    Endpoints · 17d ago↗ source
  • STAT+: Prime wins Beam arbitration, clearing path to clinic
    AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The Readout
    STAT · 17d ago↗ source
  • Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down
    Riding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been the main player: M&A. The Indianapolis-bas…
    Endpoints · 17d ago↗ source
  • Catalent to divest UK site; Rottendorf, Evonik announce manufacturing builds
    Plus, news about RoslinCT, Novo Nordisk and more. 🇬🇧 Catalent to sell UK site to Codis: The CDMO is set to take Catalent’s oral solid dose factory in Nottingham, with ...
    Endpoints · 17d ago↗ source
  • STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
    The White House is reviewing a list of three top contenders for the FDA commissioner post
    STAT · 17d ago↗ source
  • STAT+: OpenEvidence backs study that finds it beats LLMs
    In this edition of STAT Health Tech: Dueling research pitting OpenEvidence against general purpose LLMs, use of Dexcom's CGM in children, and more.
    STAT · 17d ago↗ source
  • Who’s going to run the FDA?
    RFK Jr.'s list of Covid vaccine injuries, a father's quest to cure his daughter, and more health news from Morning Rounds
    STAT · 18d ago↗ source
  • GSK walks away from Alector pact as immuno-neurology bet fizzles
    After two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s…
    Endpoints · 18d ago↗ source
  • STAT+: 931 days. The drug approval scandal hiding in plain sight
    Two years, six months, and 18 days have elapsed since Northwest Biotherapeutics submitted its brain cancer treatment for regulatory approval.
    STAT · 18d ago↗ source
  • STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
    AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
    STAT · 18d ago↗ source
  • Opinion: Your grandparents are using cannabis. Doctors can help them do it safely
    Over the past 25 years, I have treated thousands of medical cannabis patients with extremely few ill effects, one doctor writes.
    STAT · 18d ago↗ source
  • Opinion: Who benefits from classifying obesity as a disease?
    “The new wave of obesity pharmacotherapy has leaned heavily on disease framing,” writes Max Moser, drawing comparisons to the antidepressant revolution.
    STAT · 18d ago↗ source
  • STAT+: The quest to save Grace — and clear the way for rare disease patients everywhere
    How a father’s quest may shape the future of rare disease gene therapy.
    STAT · 18d ago↗ source
  • What happens on ‘MAHA Monday’?
    STAT's Alex Hogan and Chelsea Cirruzzo stopped by "MAHA Monday" at the Great American State Fair. Watch their report in this week's STATus Report.
    STAT · 18d ago↗ source
  • Updated: AstraZeneca sinks on unexpected heart drug trial failure
    AstraZeneca’s shares dropped in early trading Thursday after a heart disease treatment it is developing with Ionis Pharmaceuticals surprisingly failed in a late-stage trial. The companies had aim…
    Endpoints · 18d ago↗ source
  • STAT+: RFK Jr. plans to create list of injuries caused by Covid-19 vaccines
    It's not clear what conditions may make the list, but outside experts are watching it closely.
    STAT · 18d ago↗ source